Updates to Fact Sheets for Johnson & Johnson COVID-19 Vaccine
January 11, 2022
Ryaltris Nasal Spray Approved for Allergic Rhinitis
January 13, 2022
January 12, 2022 – In a drug safety communication, the U.S. FDA has cautioned that dental problems can occur with buprenorphine products that are taken by dissolving them in the mouth. This may include tooth decay, cavities, oral infections, and loss of teeth.
- Dental problems associated with buprenorphine dissolved in the mouth can be serious and may occur in patients who have no prior history of dental issues.
- The FDA considers buprenorphine an important tool in treating pain and opioid use disorder, and states that its benefits outweigh the potential risks of dental problems.
- The agency is requiring the addition of a warning about the risk of dental problems to both the prescribing information and medication guides for buprenorphine medications that dissolve in the mouth.